HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker’s lead
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
Collaboration Leverages the OPTF01 product to Drive Next-Generation CAR-T Development The Woodlands, Texas and Ehime, Japan, May 8, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies (Optieum), a preclinical stage company dedicated to the discovery and development of innovative Chimeric Antigen Receptor (CAR) T
Cellipont Bioservices Appoints Brett Reynolds as Chief Financial Officer to Lead Financial Strategy and Support Growth in Cell Therapy CDMO Sector
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brett Reynolds as its new Chief Financial Officer, effective immediately. Mr. Reynolds has over 25 years of experience in financial leadership roles, primarily in the life sciences industry, and succeeds Tim Heher, who recently retired from the Company.
Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
The Woodlands and Dallas, Texas, January 22, 2025/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced a partnership for cGMP manufacturing of Secretome Therapeutic’s lead asset STM-01. Under this partnership, Cellipont
ADVA Biotechnology and Cellipont Bioservices Showcase Accelerated Transition from R&D to GMP at Advanced Therapies Week 2025
BARLEV, ISRAEL, AND THE WOODLANDS, TEXAS — JANUARY 12, 2025 — ADVA Biotechnology and Cellipont Bioservices are proud to announce their participation at Advanced Therapies Week 2025, taking place in Dallas, Texas, from January 20–23, 2025. Together, they will present a showcase study highlighting how their collaboration successfully transitioned a CAR-T process from a complex manual
Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems
The Woodlands, Texas and Muskego, Wisconsin, December 10, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a strategic partnership. This collaboration enables Cellipont Bioservices to offer its clients access to the state-of-the-art Ares™ X20 fill and
Cellipont Bioservices and Mongoose Bio Sign Agreement to Advance MGB-001, its Lead TCR-T therapy, towards the Clinic for Multiple Cancers
The Woodlands and Houston, Texas, October 8, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Mongoose Bio, a private clinical-stage biopharmaceutical company pioneering next generation precision T-cell based therapies targeting solid cancers, today announced the signing of an agreement for the Technology Transfer, Process Development, and
Cellipont Bioservices Announces Darren Head As Chief Executive Officer & Minority Growth Equity Investment From HealthQuest Capital
The Woodlands, TX, October 7, 2024 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced Darren Head as Chief Executive Officer. In addition to his role as Chairman of the Board, Mr. Head brings deep institutional knowledge and a wealth of biopharmaceutical leadership experience to the role. This strategic
Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological